Left ventricular diastolic dysfunction and plasma asymmetric dimethylarginine concentration in persons with essential hypertension

Archives of Medical Science

Volumn 11, Issue 3, 2015, Pages 521-529

  Porȩba, Rafał ^a   Gać, Paweł ^a   Porȩba, Małgorzata ^a   Derkacz, Arkadiusz ^a   Chachaj, Angelika ^a   Mazur, Grzegorz ^a   Szuba, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Blood pressure; Dimethylarginines; Echocardiography

Indexed keywords

6 N,N' DIMETHYLARGININE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE MASS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84932126399     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.52354     Document Type: Article

References (37)

1. Schmieder RE. End organ damage in hypertension. Dtsch Arztebl Int 2010; 107: 866-73.
2. Banach M, Bhatia V, Feller MA, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol 2011; 107: 1208-14.
3. Gradman AH, Wilson JT. Hypertension and diastolic heart failure. Curr Cardiol Rep 2009; 11: 422-9.
4. Verma A, Solomon SD. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin North Am 2009; 93: 647-64.
5. Hatle L. How to diagnose diastolic heart failure a consensus statement. Eur Heart J 2007; 28: 2421-3.
6. Szuba A, Porȩba R, Pyszel A, Gać P, Derkacz A, Protasiewicz M. Flow mediated dilatation correlates with left ventricle diastolic dysfunction in hypertensive and healthy subjects: preliminary study. Atherosclerosis 2006; Suppl. 7: 220.
7. Landim MB, Casella Filho A, Chagas AC. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo) 2009; 64: 471-8.
8. Siekmeier R, Grammer T, März W. Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. J Cardiovasc Pharmacol Ther 2008; 13: 279-97.
9. Barylski M, Małyszko J, Rysz J, Myśliwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 2011; 7: 1055-66.
10. Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem 2010; 47: 17-28.
11. Dobashi Y, Santa T, Nakagomi K, Imai K. An automated analyzer for methylated arginines in rat plasma by high-performance liquid chromatography with post-column fluorescence reaction. Analyst 2002; 127: 54-59.
12. Teerlink T. Determination of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in biological samples by HPLC. Methods Mol Med 2005; 108: 263-74.
13. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-50.
14. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002; 105: 1503-8.
15. MacAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-40.
16. Rho J, Choi S, Seong YR, Cho WK, Kim SH, Im DS. Prmt5, which forms distinct homo-oligomers, is a member of the protein-arginine methyltransferase family. J Biol Chem 2001; 276: 11393-401.
17. Chan JR, Böger RH, Bode-Böger SM, et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 2000; 20: 1040-6.
18. Cooke JP. Does ADMA cause endothelial dysfunction. Arterioscler Thromb Vasc Biol 2000; 20: 2032-7.
19. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000; 58: 1261-6.
20. Sydow K, Fortmann SP, Fair JM, et al. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem 2010; 56: 111-20.
21. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002; 303: 131-7.
22. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
23. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-74.
24. Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality - an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009; 60: 481-7.
25. Surdacki A. L-arginine analogs-inactive markers or active agents in atherogenesis. Cardiovasc Hematol Agents Med Chem 2008; 6: 302-11.
26. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 152: 493.e1-8.
27. Saitoh M, Osanai T, Kamada T, et al. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels 2003; 18: 177-82.
28. Frøbert O, Hjortshøj SP, Simonsen U, Ravkilde J. Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization. Int J Cardiol 2008; 129: 288-91.
29. Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med 2005; 10: S27-33.
30. Sydow K, Hornig B, Arakawa N, et al. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc Med 2004; 9: 93-101.
31. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001; 37: 489-92.
32. Khan U, Hassan A, Vallance P, Markus HS. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke 2007; 38: 411-3.
33. Pikula A, Böger RH, Beiser AS, et al. Association of plasma ADMA levels with MRI markers of vascular brain injury: Framingham offspring study. Stroke 2009; 40: 2959-64.
34. Gokce N. L-arginine and hypertension. J Nutr 2004; 134: 2807S-2811S, 2818S-2819S.
35. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997; 15: 901-9.
36. th International Symposium on ADMA. Bregenz (Austria), August 28-29, 2008.
37. Schulze F, Wesemann R, Schwedhelm E, et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004; 42: 1377-83.